MDAT
MDAT (6,7-methylenedioxy-2-aminotetralin) is a conformationally restricted entactogen from the aminotetralin series, related to MDAI. Designed in academic research as a serotonin-selective, non-neurotoxic releaser, it produces MDMA-like emotional effects with minimal stimulation. Human data are essentially absent.
01 Overview
MDAT was synthesised in structure-activity work exploring rigid analogs of MDMA that release serotonin without the classic neurotoxic signature. Like its cousin MDAI, it is a serotonin-selective releaser expected to give gentle entactogenic effects.
There is little to no human pharmacology or safety data. Even serotonin-selective releasers carry serotonin-syndrome risk, and long-term safety is unknown. Likely covered by analog or psychoactive-substances legislation.
02 Mechanism
Selective serotonin-releasing agent at the serotonin transporter with minimal dopamine activity, based on a rigid aminotetralin scaffold intended to avoid MDMA-type neurotoxicity.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Light | 50–100 mg | Oral | Estimated; poorly defined potency |
| Common | 100–180 mg | Oral | Estimated, high uncertainty |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Gentle entactogenesisExpected MDMA-like openness with little stimulation, by analogy to MDAI. | Presumed mild-moderate | Unconfirmed | |
| Minimal stimulationSerotonin-selective profile implies little energising effect. | Minimal | Unconfirmed |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Serotonin syndromeSerotonin-selective releasers can still precipitate serotonin toxicity, especially in combination. | Life-threatening | Rare, elevated with serotonergic drugs | Unconfirmed | |
| Unknown long-term safetyNo chronic toxicity data exist for this obscure compound. | Moderate | Uncharacterised | Unconfirmed |